AskBio Receives FDA Clearance to Begin Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease
核心洞察
AskBio announced FDA acceptance of its IND application for AB-1009 (搜索), an AAV gene therapy for late-onset Pompe disease (搜索), advancing the program to Phase 1/2 clinical testing.
The therapy has received FDA Fast Track and Orphan Drug designations, highlighting the recognized unmet medical need for improved treatments in this rare genetic disorder.
AB-1009 (搜索) aims to address the underlying genetic defect by increasing production of the deficient enzyme, potentially reducing patients' reliance on chronic enzyme replacement therapies.
AskBio Inc., a gene therapy subsidiary of Bayer AG, has received FDA acceptance of its Investigational New Drug (IND) application for AB-1009 (搜索), an adeno-associated virus (AAV) gene therapy for late-onset Pompe disease (搜索) (LOPD). The milestone advances the program to Phase 1/Phase 2 clinical testing, with the company initiating its first clinical trial in the United States and anticipating recruitment of the first patient in early 2026.
The therapy has been granted both FDA Fast Track and Orphan Drug designations, underscoring the regulatory recognition of significant unmet medical needs in this rare genetic disorder. Fast Track designation facilitates development and expedites review of therapeutics for serious conditions, providing benefits including more frequent FDA meetings and potential eligibility for Accelerated Approval and Priority Review.
Addressing Genetic Deficiency Through Gene Therapy
"This investigational gene therapy is being studied for its potential to address the underlying genetic defect and to explore whether it can increase production of the deficient enzyme in patients with Pompe disease (搜索)," said Tahseen Mozaffar, MD, Director of the UCI Health ALS & Neuromuscular Center and Principal Investigator for the AB-1009 (搜索) Clinical Trial Program. "Patients receiving gene therapy may reduce reliance on exogenous enzyme replacement."
AB-1009 (搜索) is designed to deliver a working copy of the GAA (搜索) gene through a single intravenous infusion, aiming to help the body produce the enzyme that people with late-onset Pompe disease (搜索) lack. This approach represents a potential shift from current chronic treatment paradigms to a one-time therapeutic intervention.
Clinical Trial Design and Objectives
The PROGRESS-GT LOPD trial (NCT07282847) is structured as a single-arm, open-label, dose-escalation study assessing the safety, tolerability, and early effectiveness of AB-1009 (搜索). The Phase 1/2 study will evaluate different dose levels sequentially, starting with lower doses before advancing to higher ones once safety parameters are established.
The study represents a non-randomized, non-blinded interventional trial where all enrolled patients receive AB-1009 (搜索) at varying dose levels. The primary focus at this early stage centers on understanding safety profiles and side effects while collecting preliminary signals of therapeutic benefit.
Significant Disease Burden and Current Treatment Limitations
Pompe disease (搜索) is a rare, progressive genetic disorder estimated to affect 5,000 to 10,000 people worldwide. The condition is caused by deficiency of the enzyme acid alpha-glucosidase (搜索) (GAA (搜索)), leading to glycogen accumulation in cells and resulting in the clinical manifestations of the disease.
Late-onset Pompe disease (搜索) is characterized by progressive skeletal muscle weakness and respiratory insufficiency, with patients typically presenting with progressive proximal myopathy. The disease causes severe muscle weakness and wasting, leading to loss of mobility and can result in premature death from respiratory failure.
Currently available treatments include multiple approved enzyme replacement therapies (ERTs) with recombinant human acid alpha-glucosidase (搜索) (rhGAA), which require chronic administration. These can be used in combination with small-molecule pharmacological chaperone treatments. However, an unmet medical need persists, as some individuals receiving ERT may experience decreased clinical response over time, contributing to increased treatment demands.
Strategic Development and Collaborations
"These advancements in the AB-1009 (搜索) program, particularly the recently granted regulatory designations, highlight the recognized need for late-onset Pompe treatments," said Mansuo Shannon, PhD, Chief Scientific Officer at AskBio. "Today's news demonstrates AskBio's commitment to progressing early-stage assets into the clinic and adding those to our clinical portfolio."
The advancement of AB-1009 (搜索) was achieved through collaboration with Belief BioMed Inc. (搜索), Genethon, and Duke University (搜索). AskBio's existing clinical trial of ACTUS-101 (NCT03533673) in participants with LOPD will remain active but will no longer recruit new patients, with the trial completing with currently enrolled participants.
Market and Investment Implications
For Bayer investors, this development represents continued investment in high-risk, high-reward gene therapy platforms through AskBio. While the trial is in early Phase 1/2 stages and years from potential commercialization, successful progression could expand Bayer's rare disease portfolio and support long-term growth narratives in the competitive gene therapy landscape.
The program reinforces Bayer's strategic positioning in genetic medicines, where partnerships and platform capabilities are increasingly viewed as key value drivers. Success in this indication could differentiate AskBio's approach from competitors relying on chronic enzyme replacement or traditional therapeutic modalities.